Please assess the completion status of the following clinical trial:

Trial Title: Budesonide in Patients With Immune Mediated Enteropathies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Patients will be recruited from the Division of Gastroenterology and Hepatology and the Mayo Clinic in Rochester, MN.~* Adult patients with immune mediated enteropathies who have had improvement in symptoms and histology on oral budesonide therapy.~Exclusion Criteria~* Age \<18 years~* Positive stool gluten testing in patients with refractory celiac disease~* Small bowel malignancy or history of small bowel malignancy~* Refractory celiac disease type 2~* Post-transplant lymphoproliferative disorder associated enteropathy~* No prior improvement in symptoms and histology with budesonide therapy~* Discontinuation of budesonide therapy prior to the trial~* Other concurrent systemic corticosteroids~* Other immune mediating medications, for example but not limited to azathioprine, 6-mercaptopurine, cyclosporine, methotrexate, anti-TNF monoclonal antibodies, alpha-4 beta-7 integrin inhibiting monoclonal antibody, interleukin 12/23 inhibiting monoclonal antibody, JAK inhibitors.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Continued Budesonide (Type: NO_INTERVENTION): Patients in this arm continue budesonide at the dose they were taking at the time of enrollment in the trial
- Withdrawal of Budesonide (Type: EXPERIMENTAL): Patients are weaned off of budesonide over 2 weeks and continued off of the medication for the duration of the trial

Based on this trial design, predict the completion outcome and termination type (if applicable).